- Details
- In this discussion, Chung-Han Lee delves into his significant contributions to kidney cancer research. Dr. Lee's studies, particularly the KEYNOTE-B61 clinical trial involving non-clear cell renal cell carcinoma patients, are celebrated for their potential to revolutionize treatment practices. This specific trial evaluated the combination of lenvatinib and pembrolizumab and demonstrated a 49% resp...
|
- Details
- Pedro Barata speaks with Nazli Dizman regarding her work on a Phase I trial involving immunotherapies and gut microbiome in metastatic renal cell carcinoma. Dr. Dizman discusses the rationale behind the study, highlighting the increasing recognition of gut microbiome's impact on disease processes, including cancer. The trial tested CBM588, a bacterium used in Japan for over 50 years, which was exp...
|
- Details
- Pedro Barata converses with Andrew Hahn about his work in kidney cancer research. They delve into Dr. Hahn's study on cytoreductive nephrectomy for patients with metastatic sarcomatoid or rhabdoid renal cell carcinoma (RCC) undergoing immunotherapy-based regimens. Dr. Hahn explains the patient demographic and breakdown of treatment types, noting that despite a longer median treatment duration, cyt...
|
- Details
- Pedro Barata and Cristiane Bergerot discuss the quality of life data from the non-inferiority Phase II trial of lenvatinib/everolimus combination for the treatment of renal cell carcinoma (RCC). The study compares the starting doses of lenvatinib and finds that patients treated with a higher dose of 18mg experience better health-related quality of life and disease burden control. Dr. Bergerot asse...
|
- Details
- Pedro Barata and Martin Voss discuss a clinical trial investigating subsequent therapies for advanced Renal Cell Carcinoma (aRCC) patients. Dr. Voss provides an in-depth explanation of a new endpoint, Progression-Free Survival 2 (PFS 2), which measures time from randomization to disease progression on the next line of therapy. He emphasizes its significance in kidney cancer research, noting that i...
|
- Details
- Pedro Barata converses with Neil Shah about his research on clinical outcomes for patients with advanced RCC. They focus on two of Dr. Shah's studies: 'Real-World Clinical Outcomes of Patients with Metastatic Renal Cell Carcinoma Receiving Pembrolizumab + Axitinib vs Ipilimumab + Nivolumab’, and ‘Real-World Assessment of Changing Treatment Patterns and Sequence for Patients with Metastatic RCC in...
|
- Details
- Pedro Barata hosts Hesham Yasin to discuss his project on the implementation of artificial intelligence (AI) to analyze patient data. Dr. Yasin and his team developed a machine learning model to assess over 2,000 patients with advanced renal cell carcinoma for their risk of cardiotoxicity, in relation to their VEGF therapy. The AI, trained to recognize specific risk factors, performed at an impres...
|
- Details
- Pedro Barata and Michael Atkins discuss the significant findings of the TIVO-3 trial. The trial compared the effects of tivozanib, a selective tyrosine kinase inhibitor (TKI), and sorafenib, an older TKI in patients with relapsed or refractory advanced RCC. Dr. Atkins highlights the improved progression-free survival rates and better tolerability observed with tivozanib despite initial concerns ab...
|
- Details
- Camillo Porta provides a comprehensive overview of the CLEAR trial, an impactful research investigation into lenvatinib/pembrolizumab (lenv/pembro) as a first-line treatment for patients with advanced clear cell kidney cancer. The study showed significant survival benefits in favor of the combination treatment compared to sunitinib, a previous standard treatment for the disease. The conversation a...
|
- Details
- Pedro Barata discusses the work of his team on tivozanib, a selective androgenic therapy approved for patients with advanced renal cell carcinoma (RCC). Their research focused on non-clear cell RCC, a less common subset of RCC. The team re-examined a Phase II trial conducted several years ago, using tivozanib in a discontinuation trial. The trial enrolled over 270 patients, of whom over 45 had non...
|
